# Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung

> **NCT02713828** · PHASE1,PHASE2 · TERMINATED · sponsor: **PrECOG, LLC.** · enrollment: 13 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Lung

## Interventions

- **DRUG:** Phase I: Glembatumumab Vedotin
- **DRUG:** Phase II: Glembatumumab Vedotin

## Key facts

- **NCT ID:** NCT02713828
- **Lead sponsor:** PrECOG, LLC.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04-10
- **Primary completion:** 2018-05-29
- **Final completion:** 2018-09-26
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Company discontinued further development of study drug for this indication
- **Last updated:** 2019-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02713828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02713828, "Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02713828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*